NasdaqGM:TRVIPharmaceuticals
Why Trevi Therapeutics (TRVI) Is Down 17.2% After Doubling Down On Parallel IPF Cough Trials - And What's Next
Earlier in March 2026, Trevi Therapeutics announced it had completed an End-of-Phase 2 meeting with the FDA and secured alignment to run two global, randomized Phase 3 trials of nalbuphine ER (Haduvio) for IPF-related chronic cough, with both studies using 54 mg twice-daily dosing and cough-frequency reduction as the primary endpoint.
An interesting aspect is that Trevi plans to run two pivotal Phase 3 trials in parallel, even though the FDA indicated one could be sufficient, potentially...